Epidarex Portfolio News

EPIDAREX CAPITAL – CATALYZING INNOVATION IN HEALTH SCIENCE AND TECHNOLOGY


Category: Epidarex Portfolio News

Therapeutic Thought – Complement Immunotherapy

Apellis’ CEO, Cedric Francois, outlines the company thoughts regarding the emergence of immunotherapy as a therapeutic approach that focuses on correcting the underlying immune dysregulation rather than addressing the symptoms of a conditions.  In particular, the article discusses how the complement system plays a key role…

Five Questions with Bill Niland, Harpoon Medical CEO

By Scott Dance, The Baltimore Sun Within a year and a half of launching as a startup, Harpoon Medical’s heart surgery device could be used on humans for the first time in a matter of weeks. The Kent Island-based company expects doctors in Poland to…

Scottish Synthetic Bone Graft Company Secures $4.8m Funding

EDINBURGH, UK, December 2, 2014 –  SIRAKOSS, an innovative medical device company based in Edinburgh and Aberdeen today announced it has secured $4.8m (£3.1m) in Series-A financing from a syndicate of investors led by Epidarex Capital. Synthetic bone grafts are used in trauma, spinal and…